Spero Therapeutics

General Information

We are a multi-asset, clinical-stage biopharmaceutical company focused on identifying, developing and commercializing novel treatments for MDR bacterial infections. Our most advanced product candidate, SPR994, is designed to be the first broad-spectrum oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. Treatment with effective orally administrable antibiotics may prevent hospitalizations for serious infections and enable earlier, more convenient and cost-effective treatment of patients after hospitalization. We also have a platform technology known as our Potentiator Platform that we believe will enable us to develop drugs that will expand the spectrum and potency of existing antibiotics, including formerly inactive antibiotics, against Gram-negative bacteria.

Employees: 25
Founded: 2013
Contact Information
Address 675 Massachusetts Avenue, Cambridge, MA 02139, US
Phone Number (857) 242-1600
Web Address http://www.sperotherapeutics.com
View Prospectus: Spero Therapeutics
Financial Information
Market Cap $194.6mil
Revenues $0 mil (last 12 months)
Net Income $-35.0 mil (last 12 months)
IPO Profile
Symbol SPRO
Exchange NASDAQ
Shares (millions): 5.5
Price range $14.00 - $14.00
Est. $ Volume $77.0 mil
Manager / Joint Managers BofA Merrill Lynch/ Cowen/ Stifel
CO-Managers Oppenheimer & Co.
Expected To Trade: 11/2/2017
Status: Priced
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change